%0 Journal Article
%A Rathke, Hendrik
%A Holland-Letz, Tim
%A Mier, Walter
%A Flechsig, Paul
%A Mavriopoulou, Eleni
%A Röhrich, Manuel
%A Kopka, Klaus
%A Hohenfellner, Markus
%A Giesel, Frederik L
%A Haberkorn, Uwe A
%A Kratochwil, Clemens
%T Response prediction of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH.
%J Journal of nuclear medicine
%V 61
%N 5
%@ 2159-662X
%C New York, NY
%I Soc.
%M DKFZ-2019-02503
%P 689-695
%D 2020
%Z 2020 May;61(5):689-695
%X Neuroendocrine-like trans-differentiation of prostate cancer adenocarcinomas correlates with serum levels of Chromogranin A (CgA) and drives treatment resistance. Aim of this work was to evaluate whether CgA could serve as a response predictor for 177Lu-PSMA617 radio-ligand therapy (PSMA-RLT) in comparison to the established tumor markers. Methods: 100 consecutive patients with metastasized castration resistant prostate cancer (mCRPC) scheduled for PSMA-RLT were evaluated for prostate specific antigen (PSA), lactate dehydrogenase (LDH) and CgA at baseline and in follow-up of PSMA-RLT. Tumor-uptake of PSMA-ligand, a known predictive marker for response, was assessed as a control-variable. Results: From the 100 evaluated patients, 35 had partial remission (PR), 16 stable disease (SD), 15 mixed response (MR) and 36 progression of disease (PD). High tumor-uptake (above salivary gland uptake) translated into PR with an Odds Ratio (OR) of 60.265 (95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:31653712
%R 10.2967/jnumed.119.231431
%U https://inrepo02.dkfz.de/record/147386